drugset / Trial / NCT06850714

Evaluation of Bifidobacterium Breve PRL2020 in Preventing Antibiotic-Associated Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid

NCT06850714

RandomizedParallel-groupOpen-labelPrevention

Summary

This study aims to evaluate the efficacy and safety of the probiotic Bifidobacterium breve PRL2020 in preventing gastrointestinal and extra-intestinal side effects caused by Amoxicillin or Amoxicillin/Clavulanic Acid in pediatric patients. The study will compare a treatment group receiving the probiotic alongside antibiotics with a control group receiving antibiotics alone. The primary focus is on reducing antibiotic-induced intestinal discomfort through microbiota modulation.

Timeline

Start
2025-02-23
Primary completion
2025-06-30
Completion
2025-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bifidobacterium breve PRL2020 Other / unclassified 2e+10 cells
Background Amoxicillin Other / unclassified
Background Amoxicillin/Clavulanic Acid Unknown

Indications